Login to Your Account



Clinic Roundup


Thursday, June 2, 2011
Profectus BioSciences Inc., of Baltimore, and the HIV Vaccine Trials Network started a Phase I HIV vaccine study involving a recombinant vesicular stomatitis virus that expresses the HIV-1 gag protein. Sixty HIV-uninfected adults will be enrolled, and the trial will evaluate safety and immunogenicity of increasing doses of the vaccine. The study is being sponsored by the National Institute of Allergy and Infectious Diseases.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription